



















SUNDAY, JULY 27

	Hall ABC	Hall G	Hall F	Room 718	Room 701	Room 801	Room 107	Room 106	Room 105
8-8:45 a.m.		FRS: Novel <i>In Vivo</i> Models Of Neurodegeneration I	DEV:  Assessing The Legal And Ethical Risks Of Biomarker Testing For Alzheimer's Disease In The Clinic: Driving Towards Solutions	DEV:  Developing Topics On Real-World Data	LPR: Imaging In Neurodegenerative Diseases	LPR: From Early-Life To Late-Life: The Role Of Social And Environmental Factors In Cognitive Aging	FRS:  Neuropsychiatric Symptoms And Biomarkers I	LPR: Cognitive Reserve And Resilience	FRS:  Biomarker Findings In Global Populations I
9-10:30 a.m.		FRS: Dissecting Molecular Disease Mechanisms: Beyond APOE, Tau And Amyloid-Beta	FRS:  Untangling The Relationship Between Neurodevelopmental Disorders, Cognitive Decline And Alzheimer's Disease Risk	DEV:  Lecanemab Two Years Post-Approval: Real-World Case Series And Patient Pathway Learnings From Diverse U.S. Clinical Settings	PER: Novel Biomarkers For TDP-43 And Alpha-Synuclein	PER: Neurodegenerative Diseases Research And Care On The African Continent: A Multidisciplinary Panel	PER:  Mechanisms Of Neuropsychiatric Symptoms In MCI And Dementia	FRS: Molecular Basis Of Cognitive Resilience	FRS: Proteomic Signature Prediction And Mechanistic Insights To Cognitive Decline
10:30-11 a.m.	Hall DE	Beverage Break With Exhibits And Posters, Product Theater Presentations							
10:30 a.m.-4:15 p.m.	Hall DE	Exhibit Hall Open							
11 a.m.-12:15 p.m.	 Hall ABC	PL: Welcome And Awards Plenary Sylvia Villeneuve: Biomarker And Clinical Trajectories Of Preclinical AD							
12:15-2 p.m.	Hall DE	Boxed Lunch With Exhibits And Posters, Product Theater Presentations				808	ISTAART Intermissions		
2-3:30 p.m.	DEV:  Pathophysiology And Potential Mechanisms Of ARIA	FRS: Dissecting Molecular Disease Mechanisms: APOE, Tau And Amyloid-Beta	FRS:  Multimodal Imaging And Fluid Biomarkers In Down Syndrome	FRS:  Toward A New Era Of Anti-Amyloid Antibodies: New Mechanism Of Drug Delivery And Latest Update On Trontinemab	FRS:  Role Of Alpha Synuclein In Alzheimer's Disease	PER:  Unraveling The Genetics, Biomarkers And Reducing The Burden Of Dementia In Africa	FRS:  Neuropsychiatric Symptoms: Recognition And Implications	FRS: Role Of Genes And Environment In Risk And Resilience Of Alzheimer's And Related Disorders	FRS: Integrative Investigation Of Alzheimer's Disease And Aging Through Imaging Genetics And Proteomics
3:30-4:15 p.m.	Hall DE	Beverage Break With Exhibits And Posters, Guided Electronic Poster Tours							
3:40-4:10 p.m.	Hall DE	PL: ASK! Session with Maria Carrillo and Joanne Pike				602	PL: ASK! Q&A Plenary Session with Sylvia Villeneuve		
4:15-5:45 p.m.	FRS:  Diagnostic Criteria: Alzheimer's Association Staging And Diagnosis Criteria And The International Working Group (IWG) Criteria, Discussion And Dialogue	FRS: A Half Century Of Tau	PER:  Use Of Biomarkers In An Era With Anti-Amyloid Treatment	FRS:  Anti-Amyloid Therapies In Clinical Practice: Real World Evidence And Implementation Considerations	FRS:  LATE And Novel Biomarkers	FRS: Culturally Appropriate Cognitive Assessment In Sub-Saharan Africa: Learnings, Challenges And Opportunities	FRS: PsychAD Consortium: Unraveling Alzheimer's Disease And Neuropsychiatric Symptoms Through Comprehensive Single-Cell Genomics	FRS:  Cognitive Reserve And Brain Resilience: The Role Of Lifestyle, Diversity And Early-Life Experiences In Aging And Dementia	FRS: Advances In Focused Ultrasound For Alzheimer's Disease: The Most Powerful Sound You Will Never Hear











MONDAY, JULY 28

	Hall ABC	Hall G	Hall F	Room 718	Room 701	Room 801	Room 107	Room 106	Room 105
8-8:45 a.m.		FRS: Novel <i>In Vivo</i> Models Of Neurodegeneration II	DEV: Developing Topics On Genetics	LPR: Preclinical Drug Discovery: Targeting Amyloid	LPR: Co-Pathologies	FRS:  Vascular Contributions To Cognitive Impairment I	FRS:  Neuropsychiatric Symptoms And Biomarkers II	LPR: Leveraging Model Systems To Understand Disease And Therapeutic Mechanisms	FRS:  Biomarker Findings In Global Populations II
9-10:30 a.m.		ECBS:  Crosstalk Between Oligodendrocytes, Astrocytes And Microglia	PER:  Understanding And Interpreting Clinical Meaningfulness Of Trial Data In AD	FRS:  Preclinical Advances In Targeted Brain Delivery Of Large Molecule Therapeutics To Treat Alzheimer's Disease	FRS: Endolysosomal Dysfunction Across Neurodegenerative Diseases	FRS: The World Health Organization's Global Action Plan On Dementia: Where Are We And Where Are We Headed?	FRS:  Culturally-Sensitive Neuropsychological Evaluations	FRS: Sex-Specific Risk And Protective Factors In Alzheimer's Disease	FRS:  Longitudinal Trajectories In Preclinical AD And Amyloid Negative Individuals
10:30-11 a.m.	Hall DE	Beverage Break With Exhibits And Posters, Product Theater Presentations							
10:30 a.m.-4:15 p.m.	Hall DE	Exhibit Hall Open							
11 a.m.-12:15 p.m.	 Hall ABC	PL: Katerina Akassoglou: Neurovascular Interactions In Alzheimer's Disease: From Mechanisms To Treatments Maria Grazia Spillantini: The Multiple Facets Of Tau Pathology							
12:15-2 p.m.	Hall DE	Boxed Lunch With Exhibits And Posters, Product Theater Presentations 808 ISTAART Intermissions 603, 604, 605 ISTAART Skills Workshops							
2-3:30 p.m.	FRS:  U.S. POINTER: Top-Line Results And Implications	FRS:  Preclinical Drug Discovery Targeting Neuroinflammation For Alzheimer's Disease And Related Dementias	FRS:  Remote Collection Of Biomarkers For Alzheimer's Disease And Related Disorders	FRS:  Drug Discovery Strategies And Enabling Methodologies	FRS: Understanding And Quantifying Tau Heterogeneity In Alzheimer's Disease	FRS:  Global Solutions For Dementia Prevention: The Role Of Online Educational Programs, Coaching And Interventional Trials	FRS:  Insights From The Measurement Of Intra-Individual Variability In Cognitive Performance	FRS:  Sex Differences And Sex-Specific Factors Contributing To Women's Increased Risk Of Alzheimer's Disease	FRS:  Insights Into Disease Trajectory And Biological Staging Of AD
3:30-4:15 p.m.	Hall DE	Beverage Break With Exhibits And Posters, Guided Electronic Poster Tours							
3:40-4:10 p.m.	Hall DE	PL: <i>ASK!</i> Session with AAIC Award Winners 602 PL: <i>ASK!</i> Q&A Plenary Session with Katerina Akassoglou and Maria Grazia Spillantini							
4:15-5:45 p.m.	ECBS:  The Role Of Tau In Cerebrovascular Disease	FRS:  Neuroinflammation, Microglia, Astrocyte And Therapeutic Strategies	FRS:  Real-World Clinical Performance Of Blood Biomarkers For The Diagnosis Of Alzheimer's Disease	PER:  Translating Drug Targets From Validation Towards Clinical Candidates Within Academia	FRS:  Characterizing Sources Of Heterogeneity Within Biomarkers	FRS:  Innovations And Interventions In Dementia Care Across Global Context	FRS:  Sensory Abnormalities In Dementia	FRS:  Sex And Gender Differences In Frontotemporal Degeneration	FRS:  Timing Alzheimer's Disease Progression: Biomarker Clocks And Beyond

TUESDAY, JULY 29

	Hall ABC	Hall G	Hall F	Room 718	Room 701	Room 801	Room 107	Room 106	Room 105
8-8:45 a.m.		LPR: Novel Approaches In Neuropathology Of Alzheimer's Disease And Related Dementia	CTB:  Donanemab: Appropriate Use Recommendations And Clinical Implementation	FRS:  Early Phase Studies Exploring Diverse Mechanisms I	LPR: Non-AD Cognitive Impairment	LPR: Risk Factors For Dementia In Underrepresented Populations	FRS:  Exploring Cognitive And Psychosocial Determinants Of Dementia Outcomes I	LPR: Neuroimaging Insights Into Clinical Manifestations	LPR: Blood Based Biomarkers In Clinical Practice
9-10:30 a.m.		ECBS:  Impact Of Medical Comorbidities On Accumulation Of ADRD Neuropathology And Biomarker Readouts	DEV:  Alzheimer's Disease And Related Dementias (ADRD) Clinical Trials Early Career Investigator Oral Abstracts Session	PER: Potential Targets For AD Treatment	DEV:  Alzheimer's Disease Heterogeneity	FRS:  Social Determinants Of Health: Major Players Of Cognitive Health And Dementia	FRS:  Speech And Language Methods For The Detection And Tracking Of Cognitive Decline	FRS:  What Is Atypical For AD? From Syndrome To Biology	FRS: Tunneling Nanotubes: Connecting Immunity And Neurodegeneration
10:30-11 a.m.	Hall DE	Beverage Break With Exhibits And Posters, Product Theater Presentations							
10:30 a.m.-4:15 p.m.	Hall DE	Exhibit Hall Open And AAIC Career Fair							
11 a.m.-12:15 p.m.	 Hall ABC	PL: Inhee Mook-Jung : The Gut-Brain Axis In Alzheimer's Disease: Unraveling Pathogenesis And Exploring Novel Therapeutic Strategies Juan Fortea : Alzheimer's Disease In Down Syndrome							
12:15-2 p.m.	Hall DE	Boxed Lunch With Exhibits And Posters, Product Theater Presentations 808 ISTAART Intermissions 603, 604, 605 ISTAART Skills Workshops							
2-3:30 p.m.	FRS: New iPSC Tools To Study Neuroimmune Interactions In Alzheimer's Disease	FRS: Integrative Neuropathology Studies In Alzheimer's Disease And Related Dementia	DEV:  Evidence-Based Clinical Practice Guidelines For Detection And Diagnosis Of Cognitive Impairment Using Blood-Based Biomarkers And Cognitive Testing: Two Guideline Initiatives From The Alzheimer's Association	DEV:  Developing Topics On Clinical Trials And Cohorts	DEV:  Developing Topics On Tau Biomarkers	FRS:  Risk Factors And Biological Mechanisms For Cognitive Decline And Dementia In India	FRS:  Language As A Lens: Investigating Cognitive Processes Across Linguistic Contexts	PER:  Improving Clinical Trials For Atypical Alzheimer's Disease: A Call To Action	PER: Molecular Subtyping In ADRD To Unravel Complex Biology
3:30-4:15 p.m.	Hall DE	Beverage Break With Exhibits And Posters, Guided Electronic Poster Tours							
3:40-4:10 p.m.	Hall DE	PL: ASK! Q&A Plenary Session with Juan Fortea and Inhee Mook-Jung 602 PL: ASK! Session with Journal Editors							
4:15-5:45 p.m.	PER:  Women's Brain Health Across The Lifespan: Insights Into Aging And Dementia	ECBS:  Emerging Concepts In Basic Science Panel Discussion	FRS:  Disease Insights From Amyloid PET And Its Implications For Trials And Clinical Practice	PER:  Looking Backward And Looking Forward: A Reflection On 25 Years Of Alzheimer's Disease Research With Lessons For Future Progress	FRS:  How Generalizable Are Alzheimer's Disease Biomarker Relationships?	FRS:  Prevention Of Cognitive Decline And Dementia: Exploring The Effects Of Non-Pharmacological Interventions	DEV:  Developing Topics On Pre-Existing Conditions	FRS: Studying Tissue Samples From Rare Cohorts To Learn About Early Stage AD Pathophysiology	FRS: Genome Wide Association Studies Of Deep Phenotypes

WEDNESDAY, JULY 30

	Hall ABC	Hall G	Hall F	Room 718	Room 701	Room 801	Room 107	Room 106	Room 105
8-8:45 a.m.		LPR: Integrative Omics Studies Unravels Pathomechanisms In Alzheimer's Disease And Related Dementia	LPR: The Range Of Economic Impacts Of Dementia	DEV:  Developing Topics On Innovative Therapeutic Approaches	DEV: Developing Topics On Molecular Biology And Neuropathology	LPR: Unveiling Cognitive Enigmas With Intelligent Assessment And AI	FRS:  Exploring Cognitive And Psychosocial Determinants Of Dementia Outcomes II	LPR: Functional Studies To Reveal Novel Disease Mechanisms In Alzheimer's Disease And Related Dementia	LPR:  Emerging Technologies In Dementia Care
9-10:30 a.m.		FRS:  Multiomic Approaches To Understanding Clinical And Neuropathological Heterogeneity In Alzheimer's Disease	CTB:  Bedside Diagnosis, Management And Prognosis Communi- cation Of Primary Tauopathies Progressive Supranuclear Palsy And Corticobasal Syndrome	FRS:  Lecanemab Subcutane- ous Formulation For Maintenance Dosing: The Potential Of A New And Convenient Option For Ongoing Treatment In Early Alzheimer's Disease	FRS:  Chronic Traumatic Encephalopathy (CTE): Clinical Aspects, Pathophysiology And Biomarkers Compared To ADRD	FRS:  Artificial Intelligence- Focused Advancements In ADRD Diagnosis And Care	PER:  Tailored Exercise Interventions For Dementia Pre- vention: Bridging Research Evidence And Primary Care Practice: TEIDE Consortium	DEV: Lysosome Regulation And Signaling In Aging And Alzheimer's Disease	FRS:  Neural Circuit Hyper Excitability And Epileptic Mani- festations At The Intersection Of Alzheimer's Dis- ease Pathobiology And Aging
10:30-11 a.m.	Hall DE	Beverage Break With Exhibits And Posters, Product Theater Presentations							
10:30 a.m.-4:15 p.m.	Hall DE	Exhibit Hall Open							
11 a.m.-12:15 p.m.	 Hall ABC	PL: Sharon Naismith: Waking Up To The Importance Of Sleep In MCI And AD Katrin Andreasson: Restoring Hippocampal Glucose Metabolism Rescues Cognition Across Alzheimer's Disease Pathologies							
12:15-2 p.m.	Hall DE	Boxed Lunch With Exhibits And Posters, Product Theater Presentations 808 ISTAART Intermissions 603, 604, 605 ISTAART Skills Workshops							
2-3:30 p.m.	FRS: NIH/NIA-ADSP Artificial Intelligence And Machine Learning Consortium: Gene Discovery And Drug Development For Alzheimer's Disease	FRS: From Multi-Omics To Multi-Disease Pathways In Alzheimer's And Related Disorders	CTB:  Differential Diagnosis: If It's Not Alzheimer's Then What's Next?	PER:  Innovations In Tau-Targeting Therapies And Biomarkers For Alzheimer's Disease: Bridging Research And Clinical Practice	DEV:  Developing Topics On Biomarker Advancements	DEV:  Developing Topics On Biomarker Advancements	FRS:  Nourishing The Mind: How Diet And Gut Health Shape Cognitive Aging	FRS:  Innovative Use Of Statistical Models And Machine Learning To Enhance AD Clinical Trials	FRS: Network Alterations And Aberrant Neuronal Activity In Alzheimer's Disease: Novel Targets To Understand And Influence Disease Progression?
3:30-4:15 p.m.	Hall DE	Beverage Break With Exhibits And Posters, Guided Electronic Poster Tour							
3:40-4:10 p.m.	Hall ABC	PL: ASK! Q&A Plenary Session with Katrin Andreasson and Sharon Naismith 602 PL: ASK! Q&A Plenary Session with Gill Livingston and Tony Wyss-Coray							
4:15-5:45 p.m.	FRS:  Considerations For AD Prevention: Optimizing Clinical Trial Design	FRS: The Global Neurodegeneration Proteomics Consortium: A Public-Private Partnership For Biomarker Discovery And Disease Mechanism Insight	CTB:  Case Studies In The Evaluation, Treatment And Monitoring Of Anti-Amyloid Therapies	FRS:  Anti-Tau Etanercept (E2814) With Lecanemab Therapy In Individuals With Dominantly Inherited Alzheimer's Disease: A First Look At Baseline Characteristics And Impact Of 6-Month Lecanemab Treatment On Amyloid PET And Safety In The DIAN-TU- 001 NexGen Trial	PER: The Current State Of Registries For Participant Recruitment In Dementia Research And The Future Direction To Fast-Track Dementia Research: A Global Perspective	PER:  Transforming Dementia Care: An Introduction To The GUIDE Model	FRS:  Global Perspectives On Implementation Science In Dementia Research: Exploring Diverse Approaches And Challenges In Different Healthcare Systems And Policy Settings	FRS: The Rehabilitation Of Gamma-Secretase As A Drug Target In Alzheimer's Disease	FRS:  Awareness Of Cognitive Function Across The Alzheimer's Disease Spectrum: Biological Mechanisms, Diagnostic And Prognostic Clinical Value

	Hall ABC	Hall G	Hall F	Room 718	Room 701	Room 801	Room 107	Room 106	Room 105
9-9:45 a.m.		AAIC For All: Community: AAIC 2025 In The Neighborhood	AAIC For All: 🏥 Clinician: Clinical Highlights From AAIC 2025	DEV, FRS: Early Career Researchers In Community Engagement	LPR: Novel Biomarkers	FRS: 🏥🧠 Vascular Contributions To Cognitive Impairment II	LPR: 💡 Multi-Level Social Determinants And Brain Health	FRS: Early Phase Studies Exploring Diverse Mechanisms II	LPR: Diabetes And Dementia
9:45-11:45 a.m.	Meeting Room Foyers Beverages Available								
10-11:30 a.m.		AAIC For All: Community: AAIC 2025 Highlights	AAIC For All: 🏥🧠 Clinician: Clinical Practice Guidance And Resources	FRS: 🧠 Advancing Translational Success By Enhancing Predictive Validity In Neurodegenera- tive Diseases	FRS: 🏥🧠 Biomarkers And Neuropathology	FRS: 🏥🧠💡 Improving Dementia Detection In Primary Care: Learnings From Three Embedded, Pragmatic Clinical Trials	FRS: Harnessing The Power Of Collaborative Data Sharing And Research: Progress And Existing Barriers	FRS: Pathways Into And Out Of The Brain: Relevance To Alzheimer's Disease	FRS: 🏥🧠 United States Cost Of Dementia Model (USCDM)
11:45 a.m.- 1 p.m.	🏥 Hall ABC PL: Gill Livingston: Prevention Of Dementia: A Necessary Worldwide Agenda Tony Wyss-Coray: Brain Resilience: Understanding Brain Aging And Neurodegeneration								